Reven Pharmaceuticals Stock

Bio-Pharmaceutical Company

About Reven Pharmaceuticals Stock

Reven Holdings, Inc. is a development-stage bio-pharmaceutical company that develops and markets propriety solutions for the treatment of cardiovascular and metabolic related conditions.

Funding History

January 2014	$1.8M
January 2014	$5.0M
February 2015	$4.4M
January 2016	$10.0M
January 2017	$23.0M
January 2019	$23.0M

Management

Co-Founder & Chief Executive Officer

Peter Lange

Chief Financial Officer

Jeffrey Halverson

Chief Technology Officer

James Ervin

Chief Operating Officer

Brian Denomme

Chief Medical Officer

Fatih Uckun

Press

Reven Announces the Appointment of Eminent Physician-Scientist Fatih M. Uckun, M.D. Ph.D., Internationally Recognized for his Seminal Contributions to Oncology, Immunology and Immunity, as its Chief Medical Officer and Chief Scientific Officer

Reven - Jun, 26 2020

Other Companies

Learn More

Calysta Energy

Calysta Energy develops a new biological gas-to-liquids™ (BioGTL™) and biological gas-to-chemicals (BioGTC™) technology using natural gas.

Cellworks is a life sciences technology company involved in drug and bio-marker discovery and researches in therapeutic areas.

GoodRx believes prescription drugs should be affordable and convenient for everyone.

Spark Therapeutics is focused on the development of gene therapy.

7Age (years)

$123MTotal Funding

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Reven Pharmaceuticals or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Trending Companies

Join 130K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Why EquityZen?

EquityZen helps investors to access private companies and their employees to sell shares.

Investment opportunities posted on this website are "private placements" of securities that are not publicly traded, are subject to holding period requirements, and are intended for investors who do not need a liquid investment. Investing in private companies may be considered highly speculative and involves a high degree of risk, including the risk of substantial loss of investment. Investors must be able to afford the loss of their entire investment. See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZen’s platform.

EquityZen Securities LLC (“EquityZen Securities”) is a subsidiary of EquityZen Inc. EquityZen Securities is a broker/dealer registered with the Securities Exchange Commission and is a FINRA/SIPC member firm.

Equity securities are offered through EquityZen Securities. Check the background of this firm on FINRA’s BrokerCheck.

EquityZen.com is a website operated by EquityZen Inc. ("EquityZen"). By accessing this site and any pages thereof, you agree to be bound by our Terms of Use.
EquityZen and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners.
© 2020 EquityZen Inc. All rights reserved.